Why Scholar Rock Stock Got Socked on Monday
Key Points
A third-party manufacturing facility has apparently been flagged by the FDA.
The plant is owned by pharmaceutical industry peer Novo Nordisk.
- 10 stocks we like better than Scholar Rock ›
A potential delay in an important submission was the news item driving Scholar Rock's (NASDAQ: SRRK) share price down as the trading week kicked off. On Monday, the biotech's shares fell by more than 13% as a result, contrasting unfavorably with the 1.6% gain of the S&P 500 (SNPINDEX: ^GSPC).
A concerning inspection
In a tersely worded post on its website, Scholar Rock divulged that a third-party manufacturing facility it uses, Catalent Indiana, has been tagged by the Food and Drug Administration (FDA) as being Official Action Indicated (OAI).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
An OAI is a designation placed on a facility meaning that "regulatory and/or administrative actions are recommended," in the FDA's words. This follows an inspection by the regulator in which concerns are raised.
Catalent Indiana is owned by Novo Nordisk, best known as the developer of weight-loss drug Wegovy. The facility functions as a third-party manufacturer for other biotechs and pharmaceutical companies. Besides Scholar Rock, the list of clients includes Regeneron, among numerous others in the industry.
BLA blues
Last month, Scholar Rock suffered a setback with the FDA when the agency rejected the company's biologics license application (BLA) for its apitegromab spinal muscular atrophy (SMA) drug. It has requested a formal meeting with the FDA to help determine the next steps with the submittal, although the Catalent Indiana situation might not affect this positively.
Scholar Rock said it would continue to work with Novo Nordisk. It pledged to provide more information in its third-quarter earnings call scheduled for next month.
Should you invest $1,000 in Scholar Rock right now?
Before you buy stock in Scholar Rock, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Scholar Rock wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $657,979!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,122,746!*
Now, it’s worth noting Stock Advisor’s total average return is 1,060% — a market-crushing outperformance compared to 187% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of October 13, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
